Table 1.
Increased Adverse Events With the Concomitant Use of Ticagrelor–ARB in the PLATO Trial
| Adverse Event | Ticagrelor + ARB (n = 511) | Clopidogrel + ARB (n = 508) |
|---|---|---|
| Creatinine increase >50% | 57 (11.2%) | 36 (7.1%) |
| ACE‐I | 228 (8.4%) | 187 (6.8%) |
| Renal‐related AE | 73 (6.5%) | 48 (4.3%) |
| ACE‐I | 249 (4.1%) | 206 (3.4%) |
| Renal‐function AE | 51 (4.5%) | 31 (2.8%) |
| ACE‐I | 119 (2.0%) | 82 (1.4%) |
| Dyspnea | 176 (21.4%)a | 80 (9.9%)a |
| Entire population | 1345/9235 (14.6%) | 803/9186 (8.7%) |
| Angioedema | 14 (0.15%)b | 8 (0.09%)b |
Abbreviations: ACE‐I, angiotensin‐converting enzyme inhibitor; AE, adverse event; ARB, angiotensin receptor blocker: PLATO, Platelet Inhibition and Patient Outcomes.
a
N = 823 for ticagrelor and 807 for clopidogrel.
b
Based on entire population.